In an effort to slow the spread of COVID-19 in 2020, the Centers for Disease Control and Prevention (CDC) released guidance to delay nonessential procedures, postpone routine clinical visits, and utilize telemedicine when possible. In the case of human immunodeficiency virus (HIV), reduced access to testing and treatment can have a prolonged impact on overall transmission and management. In this report, we compare rates of HIV testing, diagnosis, treatment, and pre-exposure-prophylaxis (PrEP) utilization before and after the start of the COVID-19 pandemic, using claims data.